LYNBROOK, N.Y., Aug. 30, 2018 /PRNewswire/ -- BioSpecifics
Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that
originated and continues to develop collagenase-based therapies
with a first in class collagenase-based product marketed as
XIAFLEX® in the U.S. and Xiapex® in Europe, today
announced that BioSpecifics' President, Tom
Wegman, will present a corporate overview at the following
upcoming conferences in September.
- H.C. Wainwright 20th Annual Global Investment
Conference at 4:15 p.m. on Thursday,
September 6, 2018 in New York,
NY.
- 25th Annual BioCentury NewsMakers in The Biotech
Industry Conference at 2:00 p.m. ET on Friday, September 7, 2018 in New York, NY.
A live audio webcast of each presentation can be accessed under
the "Events and Presentation" tab in the Investors section of the
Company's website at www.biospecifics.com. An archived replay of
the webcast will be available for 30 days after the live event
concludes.
About BioSpecifics Technologies Corp.
BioSpecifics
Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for thirteen clinical indications
to date. Injectable collagenase is marketed as XIAFLEX® in the
U.S. for the treatment of Dupuytren's contracture and Peyronie's
disease by BioSpecifics' partner, Endo International plc (Endo).
XIAFLEX® is also commercialized
in Japan, Europe, Canada and Australia for
Dupuytren's contracture and for Peyronie's disease in Canada,
Europe and Australia. The CCH
research and development pipeline includes several additional
promising indications, including Phase 3 clinical trials for the
treatment of cellulite with top-line data expected in the fourth
quarter of 2018. BioSpecifics is managing the development of CCH
for the treatment of uterine fibroids the Phase 1 clinical trial is
now fully enrolled with top-line data expected in the fourth
quarter of 2018. For more information, please
visit www.biospecifics.com.
View original
content:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-two-upcoming-september-conferences-300703814.html
SOURCE BioSpecifics Technologies Corp.